Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants Authors: Lok Bahadur Shrestha, Katie Tungatt, Anupriya Aggarwal, Aija Stubis, Nicole L. Fewings, Christina Fichter, Anouschka Akerman, Chaturaka Rodrigo, Nicodemus Tedla, Sharon Lee, Andrew R. Lloyd, Fabienne Brilot, Warwick J. Britton, Anthony Kelleher, Ian D. Caterson, Mark W. Douglas, Rebecca Rockett, Stuart G. Tangye, James A. Triccas, Stuart G. Turville, Kerrie J. Sandgren, Rowena A. Bull, Anthony L. Cunningham, Anthony L. Cunningham, Anthony L. Cunningham, Tania Sorrell, Anthony Kelleher, Warwick Britton, Mark Maclean, Sharon Lee, Joanne Camilleri, Mark Douglas, Rowena Bull, Kerrie Sandgren, Yang Song, Lijun Mao, Amy Phu, Allison Sigmund, Sophie Beard, Ian Caterson Published: 2024 ABSTRACT SummaryBackgroundCurrent literature informs us that bivalent vaccines will generate a broader serum neutralizing antibody response to multiple SARS-CoV-2 variants, but studies on how this breadth relates to the memory B cell (MBC) and T cell responses are sparse. This study compared breadth of neutralising antibody, and memory B and T cell responses to monovalent or a bivalent ancestral/Omicron BA.1 COVID-19 booster vaccine.MethodsAt baseline and 1-month post-booster, neutralisation activity and frequencies of receptor binding domain (RBD)-specific MBCs and Spike-specific memory T cells were measured against a panel of variants.FindingsBoth vaccines boosted neutralising antibodies to 5 variants - Wuhan-Hu-1, Delta, BA.1, BA.5 and JN.1, the latter of which had not yet emerged at the time of sample collection. The bivalent vaccine induced a significantly larger increase in nAb against BA.1 and JN.1. Both vaccines boosted RBD-specific MBC responses to Wuhan-Hu-1, Delta, BA.1 and BA.5 variants with a significantly greater increase for BA.1 in the bivalent group. The breadth of MBCs was significantly higher in those who received the bivalent boost and correlated with nAb breadth. Both vaccines significantly boosted Spike-specific T cell responses to the Wuhan-Hu-1 and BA.5 variants, but only the bivalent vaccine boosted BA.1 responses.InterpretationThese results suggest that the bivalent vaccine confers an advantage against future novel variants due to increased frequency of broadly reactive RBD-specific B cells.FundingWork supported by 10.13039/501100009287NSW Health for the NSW Vaccine, Infection and Immunology Collaborative (VIIM). Research in contextEvidence before this studyWe searched Pubmed for relevant studies on the immunogenicity of vaccines for SARS-CoV2 between 2020 and July 2024, especially since 2022 for bivalent vaccines. Recent studies do support boosting neutralisation responses to new variants such as BA.5 and XBB.1.5 with new specific vaccine boosters. Bivalent booster vaccines were developed to combat progressively divergent variants of the Omicron family while guarding against reversion variants more closely related to the ancestral Wuhan strain. Therefore bivalent vaccines, initially containing Spike- encoding mRNA of both the ancestral strain and Omicron BA.1, and later Omicron BA.5 were developed in 2022 and administered globally during 2023. These vaccines were reported to induce superior serum neutralising antibody (nAb) potency and breadth compared to the monovalent booster, but the mechanism of this neutralising breadth is unclear. Memory B cell responses are recalled where there is high homology between prime and boost antigenic stimulation but where this is markedly different de novo responses via naïve B cells may dominate, as shown with breakthrough SARS-CoV2 infections. How this relates to bivalent vaccines containing new variants is the subject of this study. Bivalent vaccines have been reported to induce SARS-CoV-2 T cell responses which persist longer than antibodies over time but in this respect were no different to monovalent boosters.Added value of this studyWe aimed to determine the source of the breadth of serum neutralizing antibody response to multiple SARS-CoV-2 variants by bivalent vaccines, whether it is it a result of a polyclonal response with multiple variant specific responses working together, or is it a result of an enrichment of broadly neutralizing responses? This distinction is important to understand as it will likely predict how well these responses can protect against future variants. Here we show that both vaccines boosted protective antibodies to multiple SARS-CoV-2 variants, however the bivalent vaccine induced superior responses to BA.1 and JN.1, a variant which was yet to emerge at the time of the trial. SARS-CoV-2 specific memory B cells (MBCs) were also boosted by both vaccines, but the breadth of MBCs for recognising SARS-CoV-2 variants was greater in those participants who received the bivalent vaccine and correlated with protective antibodies. T cell responses were also enhanced by both vaccines and were significantly higher towards BA.1 in the bivalent vaccine group than the monovalent. These findings suggest that the bivalent vaccine generates SARS-CoV-2 MBCs that do enrich broadly neutralising responses, that are superior in protecting against future variants. In support of this statement, we found that people that had received the bivalent vaccine did have superior neutralizing activity against the current JN.1 variant in circulation. The findings from this vaccination study extend beyond previous reports that BA.1 breakthrough infection similarly generates MBCs with superior breadth.Implications of all the available evidenceThe data generated here will be useful for advising future vaccine strategies and baseline data for further comparisons as new variant vaccines, such as XBB.1.5 are rolled out. Data may also be relevant for public health modelling tools for estimating population susceptibility. Research in context Evidence before this study We searched Pubmed for relevant studies on the immunogenicity of vaccines for SARS-CoV2 between 2020 and July 2024, especially since 2022 for bivalent vaccines. Recent studies do support boosting neutralisation responses to new variants such as BA.5 and XBB.1.5 with new specific vaccine boosters. Bivalent booster vaccines were developed to combat progressively divergent variants of the Omicron family while guarding against reversion variants more closely related to the ancestral Wuhan strain. Therefore bivalent vaccines, initially containing Spike- encoding mRNA of both the ancestral strain and Omicron BA.1, and later Omicron BA.5 were developed in 2022 and administered globally during 2023. These vaccines were reported to induce superior serum neutralising antibody (nAb) potency and breadth compared to the monovalent booster, but the mechanism of this neutralising breadth is unclear. Memory B cell responses are recalled where there is high homology between prime and boost antigenic stimulation but where this is markedly different de novo responses via naïve B cells may dominate, as shown with breakthrough SARS-CoV2 infections. How this relates to bivalent vaccines containing new variants is the subject of this study. Bivalent vaccines have been reported to induce SARS-CoV-2 T cell responses which persist longer than antibodies over time but in this respect were no different to monovalent boosters. Added value of this study We aimed to determine the source of the breadth of serum neutralizing antibody response to multiple SARS-CoV-2 variants by bivalent vaccines, whether it is it a result of a polyclonal response with multiple variant specific responses working together, or is it a result of an enrichment of broadly neutralizing responses? This distinction is important to understand as it will likely predict how well these responses can protect against future variants. Here we show that both vaccines boosted protective antibodies to multiple SARS-CoV-2 variants, however the bivalent vaccine induced superior responses to BA.1 and JN.1, a variant which was yet to emerge at the time of the trial. SARS-CoV-2 specific memory B cells (MBCs) were also boosted by both vaccines, but the breadth of MBCs for recognising SARS-CoV-2 variants was greater in those participants who received the bivalent vaccine and correlated with protective antibodies. T cell responses were also enhanced by both vaccines and were significantly higher towards BA.1 in the bivalent vaccine group than the monovalent. These findings suggest that the bivalent vaccine generates SARS-CoV-2 MBCs that do enrich broadly neutralising responses, that are superior in protecting against future variants. In support of this statement, we found that people that had received the bivalent vaccine did have superior neutralizing activity against the current JN.1 variant in circulation. The findings from this vaccination study extend beyond previous reports that BA.1 breakthrough infection similarly generates MBCs with superior breadth. Implications of all the available evidence The data generated here will be useful for advising future vaccine strategies and baseline data for further comparisons as new variant vaccines, such as XBB.1.5 are rolled out. Data may also be relevant for public health modelling tools for estimating population susceptibility. Introduction Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has progressed through many divergent lineages since its emergence in December 2019. The Omicron BA.2.86 sub-lineage JN.1 represented the globally dominant lineage in early 2024.1, 2, 3 This continuing emergence of divergent variants, their ongoing and evolving resistance to neutralisation responses and concerns about waning immunity have prompted the development of bivalent booster vaccines.1,4,5 From September 2022, these bivalent vaccines, containing Spike-encoding mRNA of both the ancestral strain and Omicron BA.1,6 were first administered, with Omicron BA.54 following later. Several studies have suggested that booster doses of the bivalent Omicron vaccine induces superior serum neutralising antibody (nAb) potency and breadth compared to the monovalent booster,6, 7, 8 but studies comparing how this relates to the breadth of the memory B cell (MBC) and T cell responses are sparse. Specifically, it is unclear if this increase in neutralising breadth is a result of an increase in a polyvalent response with unique specificities to multiple variants, or it is an increase in nAb targeting conserved epitopes. Recent studies do support boosting neutralisation responses to new variants such as BA.59 and more recently XBB.1.510 with new specific vaccine boosters. However, although mRNA based vaccines can be rapidly reformulated to address such dominant circulating lineages, by the time they are available, additional divergent lineages have appeared, as with the XBB.1.5 vaccine and the latter appearance of BA.2.86 derived lineages.11 Vaccine-induced SARS-CoV-2 T cell responses, which persist longer than antibodies over time, have been reported to be modestly boosted by bivalent vaccines but with no appreciable difference from monovalent boosters.7,12,13 However, booster doses do play a key role in restoring protective levels of immunity and improving the affinity of MBCs by recalling those MBCs and allowing them to undergo further rounds of somatic hypermutation and selection, particularly in the situation where there is high sequence homology between the prime and boost antigen.14, 15, 16, 17 However, as the antigenic diversity increases between the prime and boost antigen, the secondary germinal centres may become increasingly dominated by naïve B cells,18 with de novo responses driving the variant-specific responses.19 As SARS-CoV-2 variants are expected to continue to emerge, it will be of greatest benefit to have a vaccine strategy that broadens memory response to protective epitopes that are highly conserved, in order to target future variants. Encouragingly, an examination of the breadth of binding of individual B cells following natural breakthrough infections by Omicron BA.1 revealed MBCs with greater breadth of binding compared to vaccinated individuals with no breakthrough infections.20 In this study, we examined whether the bivalent ancestral/Omicron BA.1 vaccine (mRNA-1273.214) induced superior immune responses, in magnitude and/or breadth, compared to the monovalent ancestral vaccine (BNT162b2 or mRNA-1273), whether it preferentially promotes the induction of broadly binding MBCs and whether this correlated with T cell responses. Methods Study cohort This sub-study is a part of a prospective cohort study conducted by the Vaccine, Infection and Immunology (VIIM) Collaborative Research Group in New South Wales, Australia. VIIM recruited 199 participants starting in May 2021 for immunogenicity studies. These participants had no prior COVID-19 vaccination or infection, which was possible due to Australia’s strict quarantine during 2020 and 2021. These participants had blood collected at baseline (pre vaccination). Repeat blood was collected at dose 2 (3 weeks post dose 1), and 3, 6, 12 and 24 months post dose 2. Participants received a third dose, approximately 5 months post dose 2. Their vaccination and infection history was documented as well as basic demographics. Thirty one of the VIIM subjects were recruited for this sub-study between April 2022 and Jan 2023, to receive a fourth vaccine dose, either the monovalent ancestral vaccine (mRNA-1273 or BNT162b2) or the bivalent ancestral/Omicron BA.1 vaccine (mRNA-1273.214). The monovalent group were recruited between (26/4/2022-10/8/2022) and the bivalent group were recruited between (15/12/2022-10/1/2023). The subjects were recruited into the different arms based on their choice and vaccine availability at the time of recruitment. Of these 31 participants, 18 received the bivalent vaccine and 13 received the monovalent vaccine. This fourth dose was administered a median of 182 days (132–188 days) after their third dose in the monovalent group, and 340.5 days (315–355.25 days) in the bivalent group. Blood was collected for this sub-study just prior to administration of the booster (pre-dose 4) and 1-month post-vaccination (post-dose 4). Blood was processed on the day of collection with PBMCs stored locally in the liquid nitrogen and serum stored in the NSW Health Statewide Biobanks until use. In some instances, participants were grouped for analysis based on whether they had had a SARS-CoV-2 infection, confirmed by PCR testing or rapid antigen testing or the presence of nucleocapsid antibodies, prior to receiving their fourth vaccine dose. 12/31 participants had had a prior infection. Ethics The study was approved by the Western Sydney Local Health District Human Research Ethics Committee (WSLHD HREC) (2021/ETH00442), written informed consent was obtained for the main study and this sub-study. All primary viral isolates used herein were obtained from de-identified remnant diagnostic swabs that had completed all diagnostic testing under approval by the New South Wales Chief Health Officer following independent scientific review and as outlined in the ADAPT ethics protocol 2020/ETH00964. Abbott architect SARS-CoV-2 IgG IgG antibodies to the Nucleocapsid protein (N) of SARS-CoV-2 were detected using Architect SARS-CoV-2 IgG (Abbott Diagnostics, Sydney, NSW Australia) as previously described.21 Viral isolation, propagation, and titration SARS-CoV-2 variants were isolated and characterised as previously described.22 Briefly, diagnostic respiratory specimens that tested positive for SARS-CoV-2 (RT-qPCR, Seegene Allplex SARS-CoV-2) were sterile-filtered through 0.22 μm column-filters at 10,000×g and serially diluted (1:3) on HAT-24 cells. After confirmation of cytopathic effect, 300 μL of pooled culture supernatant from infected wells were added to VeroE6-TMPRSS2 (Vero-T) cells23 in a 6-well plate (0.5 × 106 cells/well in 2 mL MEM supplemented with 2% (v/v) fetal calf serum) and incubated until significant cytopathic effects accumulated (50% of the cell sheet was intact) over 24–72 h. Supernatant was cleared by centrifugation (2000×g for 5 min) at a later time point, frozen at −80 °C (passage 2), then titrated to determine median 50% Tissue Culture Infectious Dose (TCID50/mL) on Vero-T cells following Spearman-Karber method.23,24 Larger volumes were then generated by inoculation of 1 × 107 Vero-T cells at a MOI of 0.025 initially in 500 μL for 30 min at 37 °C and then latter culture for 24 h in a T75 cm2 flask. Supernatant was cleared by centrifugation (2000×g for 5 min) and frozen at −80 °C. Overnight titres (20 h post-infection) were then determined as previously described using the HAT-24 cell line.25 Sequence identity and integrity of all expanded isolates was confirmed for virus via whole-genome viral sequencing using the Oxford Nanopore Technology platform, as previously described.22,23,26 SARS-CoV-2 microneutralisation assay The rapid high-content neutralisation assay with HAT-24 cells has been previously described.22,25 Briefly, human blood serum or plasma samples was serially diluted 1:2 with a starting dilution of 1:10 in a final volume of 50 μL. These diluted serum/plasma samples were then mixed together in duplicate with an 50 μL of SARS-CoV-2 virus solution that had been standardised to contain an amount of virus expected to infect 50% of cultured cells (2 times the half maximal viral infective dose or 2 × VE50).27 After mixing the diluted serum/plasma samples with the SARS-CoV-2 virus solution, the mixtures were incubated together at 37 °C for 1 h to allow any antibodies present in the serum/plasma to neutralise the virus. Next, 40 μL of each serum/virus mixture were added to an equal volume of HAT-24 cells (1.6 × 104 cells total per well in total volume of 40 μL) that had been pre-plated into 384-well plates and stained with the live nuclear fluorescence dye NucBlue at 5% (v/v). The plates containing the cells and serum/virus mixtures were then incubated for 20 h. With greater viral replication, the concentration of nuclei incorporated into large syncytial foci reduced nuclei counts in a dose dependent manner. This was then enumerated using automated high-content fluorescence microscope system to count the number of fluorescently stained cell nuclei present in each well. Neutralisation reduced syncytial foci and increased the ability to resolve and count nuclei. The % neutralisation was calculated with the formula: %N = (D – (1 – Q)) × 100/D as previously described,22,25 where “Q” is a well’s nuclei count divided by the average count for uninfected controls and D = 1 – Q for the average count of positive infection controls. Data was normalised to generate sigmoidal dose–response curves (average counts for mock-infected controls = 100%, and average counts for highest viral concentration = 0%) and VE50 values were obtained with GraphPad Prism software. Limit of detection for neutralisation assays is 1/20 ID as it is the lowest serum dilution step that permits detection in the live virus neutralisation read out. Samples that were below the limit of detection (<20) were assigned an arbitrary value of 20. SARS-CoV-2 RBD recombinant protein production His and Avi-tagged SARS-CoV-2 rRBD proteins were either made in-house (SARS-CoV-2 Wuhan-Hu-1, Delta variant, Omicron BA.5) or purchased from Sino Biological (Omicron BA.1). The Delta variant plasmid was kindly provided by Prof. Daniel Christ (Garvan Institute, Sydney, Australia) and Omicron BA.5 was purchased from GeneScript. The protocol for in-house cloning of Wuhan-Hu-1 plasmid has been described elsewhere.28,29 Briefly, SARS-CoV-2 RBD (residues 319–541), with a N-terminal human Ig kappa leader sequence and C-terminal Avi- and His-tags, was cloned into pCEP4 (Invitrogen) or pcDNA3.1. Expi293-Freestyle cells (ThermoFisher Scientific) were cultured at 37 °C and 8% CO2 in growth medium containing Expi293 Expression Medium (ThermoFisher Scientific). The plasmid was transiently transfected into Expi293-Freestyle cells as follows: 1.5 × 108 total cells (50 mL transfection) were mixed with 50 μg of plasmid, 160 μL of Expifectamin and 6 mL of OptiMEM-I and left overnight at 37 °C in a shaking incubator. The following day 300 μL of ExpiFectamine Enhancer 1 and 3 mL of ExpiFectamine Enhancer 2 was added to the cells before the cells were left in culture for a further 48 h. After a total of 72 h in culture, the cell culture was collected and centrifuged 4000×g for 20 min at 4 °C to remove cellular debris. The supernatant was clarified by passing twice through a 0.22 μm filter. The His-tagged protein was then affinity purified from the cell supernatant using a HisTrap HP Column (GE Healthcare) and eluted with imidazole. The purified protein was then buffer exchanged and concentrated in sterile DPBS by centrifuging at 4000×g for 30 min at 4 °C in a 10,000 MWCO Vivaspin centrifugal concentrator (Sartorius) and stored at −80 °C. The recombinant RBD was biotinylated using the Avitag as described by the manufacturer (Genecopeia). Tetramerisation of the RBD proteins The tetramerisation method was adapted from a previously published protocol.29,30 In brief, biotinylated RBDs were incubated with Streptavidin-PE (SA-PE; Molecular probes; ThermoFisher Scientific), Streptavidin-APC (BD), Streptavidin-BV650 (BD) and Streptavidin-BB515 (BD) in a molar ratio of 4:1. The streptavidin-fluorochrome dye was added stepwise in 1/10th volume increments to the biotinylated protein, for a total of 10 times with a 10 min incubation at 4 °C, in a rotating bioreactor, protected from light. Staining and acquisition of memory B cells Cryopreserved PBMCs were thawed rapidly in a 37 °C water bath and washed with pre-warmed RPMI media supplemented with 2 mM L-glutamine, 50 IU/mL penicillin, 50 mg/mL streptomycin and 10% heat inactivated foetal calf serum (Sigma). The cells were resuspended in FACS wash buffer (DPBS + 1% BSA) and counted. All subsequent incubations were performed protected from light. Cells were washed with FACS wash buffer, followed by incubation with 5 μL Human Fc block (BD) per 2 × 106 cells at room temperature for 10 min to block non-specific antibody binding. The cells were washed again with FACS wash buffer and resuspended. SARS-CoV-2 rRBD cocktail was prepared by mixing 0.5 mg/mL per sample of each SARS-CoV-2 variant tetramer at 4 °C. The rRBD cocktail was added to the cells and incubated at 4 °C for 30 min. All consecutive steps were done either at 4 °C or on ice and washed twice. The cells were stained for 30 min at 4 °C with an antibody cocktail containing BD brilliant buffer plus, CD21 BV421, IgD BV510, CD10 BV605, CD19 BV711, IgG BV786 and CD20 APC-H7, CD27 PE-CF594, CD38 BUV395, CD83 BUV737, CXCR4 PE-Cy7, HLA-DR R718 and CD24 BB700. All the antibody reagents were obtained from BD Bioscience. The cells were washed twice with FACS buffer at 4 °C and resuspended in 1% formaldehyde. The 7-AAD viability dye (Invitrogen) was added at 5 μL per sample and the cells were filtered before acquiring. Samples were acquired on a 5-laser Cytek Aurora flow cytometer and data was analysed using FlowJo version 10.7.1 (TreeStar). For Boolean analysis of variant cross-binding MBCs, data were imported into SPICE 6.1 software.31 Boolean gating was applied to assess the binding of MBCs to combinations of each of the four SARS-CoV-2 RBD tetramers. Specifically, gates were created for each tetramers, and logical AND combinations were used to quantify cells binding to single variants, 2 variants, 3 variants and all four variants. IFN-γ and IL-2 FluoroSpot assay Due to sample availability, only 17/18 participants in the bivalent group were assessed for T cell responses. Cryopreserved PBMC were thawed, DNAse treated (30 mg/mL, Worthington Biochem) and rested overnight in RPMI-1640 medium (Lonza) supplemented with 10% FCS and 1× penicillin-streptomycin (Thermo Fisher Scientific). PBMCs were plated in the same media at a density of 180–250 × 103 cells per well in pre-coated IFN-γ/IL-2 FluoroSpot plates (Mabtech) as previously described.32 Samples were stimulated in duplicate with overlapping peptide pools that spanned the complete Spike protein of Wuhan-Hu-1 SARS-CoV-2 variant (PepTivator SARS-CoV-2 Prot_S Complete), or selectively covered the mutated regions of the Spike protein in the BA.1 (PepTivator SARS-CoV-2 Prot_S B.1.1.529/BA.1 Mutation Pool) or the BA.5 (PepTivator SARS-CoV-2 Prot_S B.1.1.529/BA.5 Mutation Pool; Miltenyi Biotech) variants as compared to the Wuhan-Hu-1 sequence. All peptide pools were added at 1 μg/mL. PHA-L (10 μg/mL, Abacus DX) or PBS was used for positive and negative controls, respectively. Plates were incubated for 20 h at 37 °C and 5% CO2 followed by assay development as per the manufacturer’s instructions. The fluorescence spot forming units (SFU) for each well were detected using an IRIS Reader (Mabtech). The mean number of responding cells in unstimulated wells was deducted from stimulated samples to account for background expression. Results were expressed as SFU per 1 × 106 PBMC for IFN-γ and IL-2 single and dual cytokine-producing cells, or as average relative spot volume (RSV). Statistical analyses All data obtained in this study were entered on MS excel and analyses were performed either on GraphPad Prism 10, R studio version 2023.12.1 + 402 or SPSS 25. The datasets were tested for normality with the Shapiro–Wilk test; categorical variables are expressed as absolute numbers and percentages while continuous variables were expressed as median (IQR) or mean ± standard deviation where appropriate. Statistically significant associations were explored with appropriate non-parametric tests (e.g., Wilcoxon matched pairs signed rank test to compare between pre-booster and post-booster, Mann Whitney U test or Kruskal Wallis test to compare between vaccine types). To adjust for the effect of confounders we tested if age, sex, prior SARS-CoV-2 infection (yes or no), and time to blood draw since the booster dose was statistically significantly different between the monovalent and bivalent groups and if so, those variables were used as co-variates with vaccine status (monovalent vs bivalent) in a multiple linear regression (adjusted analysis) to explore if vaccine status was independently associated with the each log transformed dependent variable. We utilised all available eligible samples in this substudy, hence a sample size calculation was not done. p-values < 0.05 were considered statistically significant. Role of funders The funders had no role in the study design, data collection and analysis, data interpretation, decision to publish and manuscript preparation. Results Study protocol and cohort demographics Thirty one participants previously vaccinated with three doses of either the Pfizer BNT162b2 monovalent or Moderna mRNA-1273 monovalent vaccine at 0, 1 and 6 months and followed for a total of ∼12 months prior to this sub-study, were recruited to compare the level and breadth of the nAb, T cells and MBCs following a fourth vaccine dose with either the mRNA-1273 or BNT162b2 monovalent ancestral vaccine (n = 13, median age 66, 62% female) or the mRNA-1273.214 bivalent ancestral/Omicron BA.1 vaccine (n = 18, median age 47.5, 17% female) (Table 1). These fourth dose vaccines will hereafter be referred to as the monovalent and bivalent vaccines. The interval between the baseline and post-booster timepoint was a median of 32 days for the monovalent group and 28.5 days for the bivalent group (Table 1).Table 1Characteristics of bivalent BA.1 vaccine booster study participants (n = 31).Participant characteristicsMonovalent boosterBivalent boosterNumber of individuals1318Age at study commencement (median, IQR, years)66 (53–69)47.5 (33.5–56.75)Sex Male (n, n%)5 (38.5%)15 (83.3%) Female (n, n%)8 (61.5%)3 (16.7%)SARS-CoV-2 infection prior to or during study period Yes (n, n%)3 (23.1%)9 (50%)Vaccine regimen 4× BNT162b2 Monovalent11n/a 3× BNT162b2 Monovalent then 1× mRNA-1273 Monovalent2n/a 3× BNT162b2 Monovalent then 1× mRNA-1273 Bivalent BA.1n/a16 2× BNT162b2 Monovalent, then 1× mRNA-1273 Monovalent then 1× mRNA-1273 Bivalent BA.1n/a2Days between Dose 4 and follow-up sample collection (median, IQR)32 (29–43.5)28.5 (28–32) Table 1Characteristics of bivalent BA.1 vaccine booster study participants (n = 31).Participant characteristicsMonovalent boosterBivalent boosterNumber of individuals1318Age at study commencement (median, IQR, years)66 (53–69)47.5 (33.5–56.75)Sex Male (n, n%)5 (38.5%)15 (83.3%) Female (n, n%)8 (61.5%)3 (16.7%)SARS-CoV-2 infection prior to or during study period Yes (n, n%)3 (23.1%)9 (50%)Vaccine regimen 4× BNT162b2 Monovalent11n/a 3× BNT162b2 Monovalent then 1× mRNA-1273 Monovalent2n/a 3× BNT162b2 Monovalent then 1× mRNA-1273 Bivalent BA.1n/a16 2× BNT162b2 Monovalent, then 1× mRNA-1273 Monovalent then 1× mRNA-1273 Bivalent BA.1n/a2Days between Dose 4 and follow-up sample collection (median, IQR)32 (29–43.5)28.5 (28–32) Characteristics of bivalent BA.1 vaccine booster study participants (n = 31). SARS-CoV-2 infection episodes prior to the booster sub-study period were confirmed either by the history of PCR or Rapid Antigen Test (RAT) results provided by the subject or by screening for Ab against SARS-CoV-2 Nucleocapsid antigen using ELISA. The date of infection and diagnostic method is documented in Supplementary Table S1. The probable SARS-CoV-2 variant was assumed based on date of diagnosis and the dominant circulating variant in the Australian population at that time (Fig. 1A).33Fig. 1(A) The waves of SARS-CoV-2 variants in Australia as numbers of sequenced genomes deposited on GSAID database (https://gisaid.org/). (B) Trend in neutralisation antibody titres across different variants of SARS-CoV-2 post-boost in the monovalent and bivalent vaccine group. Lines connect data points that belong to the same individual. The limit of detection in the neutralisation assays is ID50 = 20. (C) Neutralisation antibody titres across different variants of SARS-CoV-2 in the monovalent and bivalent vaccine groups. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection, respectively. The median titres are labelled. Lines connect data points that belong to the same individual. Pre- and post-boost timepoints were compared by paired Wilcoxon sign ranked test. (D) Comparison of neutralising antibody titre between monovalent and bivalent vaccine post-boost. Grey colour represents the monovalent vaccine group while magenta represents bivalent. Significance was measured using Mann–Whitney tests. (E) Fold change in neutralisation antibody titres between pre- and post-boost, across different variants of SARS-CoV-2 in the monovalent and bivalent vaccine groups. Significance was measured using Mann–Whitney tests. All box plots display the median and interquartile range, and whiskers display min to max. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. (A) The waves of SARS-CoV-2 variants in Australia as numbers of sequenced genomes deposited on GSAID database (https://gisaid.org/). (B) Trend in neutralisation antibody titres across different variants of SARS-CoV-2 post-boost in the monovalent and bivalent vaccine group. Lines connect data points that belong to the same individual. The limit of detection in the neutralisation assays is ID50 = 20. (C) Neutralisation antibody titres across different variants of SARS-CoV-2 in the monovalent and bivalent vaccine groups. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection, respectively. The median titres are labelled. Lines connect data points that belong to the same individual. Pre- and post-boost timepoints were compared by paired Wilcoxon sign ranked test. (D) Comparison of neutralising antibody titre between monovalent and bivalent vaccine post-boost. Grey colour represents the monovalent vaccine group while magenta represents bivalent. Significance was measured using Mann–Whitney tests. (E) Fold change in neutralisation antibody titres between pre- and post-boost, across different variants of SARS-CoV-2 in the monovalent and bivalent vaccine groups. Significance was measured using Mann–Whitney tests. All box plots display the median and interquartile range, and whiskers display min to max. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. Bivalent BA.1 vaccine induced superior neutralising antibody against all variants A live virus microneutralisation test against Wuhan-Hu-1, Delta, BA.1, BA.5 and JN.1 variants was performed for the different samples (Fig. 1B). The neutralisation titre increased post-boost in both the monovalent and bivalent vaccine groups for each of the variants tested (Fig. 1C). Pre-boost, there was no significant difference in the nAb titre for each variant (Supplementary Fig. S1); however, post-boost the bivalent vaccine group generated significantly higher neutralising titres compared to the monovalent group for all 5 variants (Fig. 1D). This included against the JN.1 variant, which had not yet emerged at the time of the specimen collection for this study (Fig. 1D). The bivalent vaccine induced a significantly higher fold change in nAb to the BA.1 and JN.1 variants than the monovalent vaccine, with a similar trend observed for the BA.5 variant (Fig. 1E). While participants with prior SARS-CoV-2 infection had significantly higher nAb titres to all variants tested at baseline than those participants without prior infection, prior infection status did not affect the pattern of nAb increase between pre- and post-boost timepoints for all variants (Supplementary Fig. S2A). Participants without prior infection had a significantly greater fold change in nAb titres to both the Wuhan-Hu-1 and Delta variants following booster vaccination (Supplementary Fig. S2B) but not BA.1, BA.5 and JN.1. Therefore, prior infection status alone could not account for the pattern of increased fold change in nAb observed when comparing the monovalent and bivalent vaccine groups (Fig. 1E). Bivalent BA.1 vaccine induces a greater magnitude of MBC responses against Omicron BA.1 compared to the monovalent vaccine booster Using a 17-colour flow cytometry panel comprising four SARS-CoV-2 RBD variants (Wuhan-Hu-1, Delta, Omicron BA.1 and Omicron BA.5), mature B cells (CD19+CD20+CD10-) were gated and then analysed for RBD-specific CD27+ MBCs (Supplementary Fig. S3) in both the monovalent and bivalent vaccine group at baseline and 1-month post-booster. Both monovalent and bivalent vaccines significantly boosted RBD-specific MBCs against all four variants (Fig. 2A). However, BA.1 was the only variant which showed a difference in RBD-specific MBC between the monovalent and bivalent vaccine groups post-boost (Fig. 2A). The monovalent and bivalent groups had similar fold increases in RBD MBCs specific for Wuhan-Hu-1, Delta, and BA.5 variant, but the bivalent vaccine group had a significantly higher fold-change in RBD-specific MBCs for BA.1 compared to the monovalent vaccine group (Fig. 2B).Fig. 2(A) Comparison of RBD-specific memory B cells (MBCs; CD27+IgG+) per million B cell frequency pre- and post-boost as measured by RBD tetramer binding in flow cytometry. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection while circles and triangles represent pre- and post-boost timepoints, respectively. (B) Fold change in RBD-specific MBC frequency between the pre- and post-boost for each vaccine group’s response to each variant. Grey boxes represent monovalent vaccine while magenta represent bivalent vaccine. (C) MBC binding to multiple RBDs (≥2 RBD tetramers) were compared pre- and post-boost for each vaccine group. (D) Tetramer binding combinations of cross-reactive MBCs post-boost. W; Wuhan-Hu-1. D; Delta. B1; BA.1. B5; BA.5. Grey boxes represent monovalent vaccine while magenta represent bivalent vaccine. (E) Boolean analysis of cross-binding MBC populations in monovalent and bivalent vaccine post-boost. Pie charts indicate the fraction of MBCs that bind to two, three, or four variant RBDs. Each coloured arc indicates a specific RBD variant. All box plots display the median and interquartile range, and whiskers display min to max. Statistical comparison between pre- and post-boost was done using paired Wilcoxon signed ranked test while Mann–Whitney test was employed to compare the monovalent vs bivalent vaccine. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. MBC, CD19+CD20+CD10-CD27+. (A) Comparison of RBD-specific memory B cells (MBCs; CD27+IgG+) per million B cell frequency pre- and post-boost as measured by RBD tetramer binding in flow cytometry. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection while circles and triangles represent pre- and post-boost timepoints, respectively. (B) Fold change in RBD-specific MBC frequency between the pre- and post-boost for each vaccine group’s response to each variant. Grey boxes represent monovalent vaccine while magenta represent bivalent vaccine. (C) MBC binding to multiple RBDs (≥2 RBD tetramers) were compared pre- and post-boost for each vaccine group. (D) Tetramer binding combinations of cross-reactive MBCs post-boost. W; Wuhan-Hu-1. D; Delta. B1; BA.1. B5; BA.5. Grey boxes represent monovalent vaccine while magenta represent bivalent vaccine. (E) Boolean analysis of cross-binding MBC populations in monovalent and bivalent vaccine post-boost. Pie charts indicate the fraction of MBCs that bind to two, three, or four variant RBDs. Each coloured arc indicates a specific RBD variant. All box plots display the median and interquartile range, and whiskers display min to max. Statistical comparison between pre- and post-boost was done using paired Wilcoxon signed ranked test while Mann–Whitney test was employed to compare the monovalent vs bivalent vaccine. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. MBC, CD19+CD20+CD10-CD27+. The bivalent vaccine induces RBD-specific MBC antibodies with greater breadth To explore whether bivalent booster immunisation induces a general broadening of the polyclonal serum antibody repertoire with unique specificities or whether there is an enrichment of broadly nAbs, a Boolean gating strategy was used to characterise the cross-reactivity of each individual MBC to each of the four RBD variant tetramers. The number of RBD + MBC binding to multiple variants (≥2 variants RBD) was increased post-boost in both vaccine types, but the increase was greatest in the bivalent booster group (Fig. 2C). The Boolean analysis of RBD-binding capacities revealed that specifically, there was a significant increase in cross-reactive MBCs towards Wuhan-Hu-1+BA.1+ and Delta + BA.1+BA.5+ in the bivalent boost group (Fig. 2D). When looking at the proportion of MBCs binding multiple RBD variants, there are substantially more MBCs capable of binding three variants in the bivalent group post-boost than in the monovalent group (Fig. 2E). This is largely influenced by the MBCs binding Delta, BA.1 and BA.5 variants. This suggests that the bivalent booster does result in greater cross-reactive MBCs in vaccinees. To confirm that the increase in frequency of cross-reactive MBCs post-booster was due to the vaccine type and not the participants’ infection history, the frequencies of MBCs binding RBD tetramers were compared from individual or combinations of multiple variants, between the infected vs non-infected subjects. There was no significant difference between these MBC features post-booster between the infected vs non-infected subjects (Supplementary Table S2) indicating that the differences shown in Fig. 2 are genuinely induced by the bivalent booster vaccine. The bivalent vaccine induces broader T cell responses T cell responses following 20 h stimulation with one of three peptide pools against Wuhan-Hu-1, BA.1 and BA.5, respectively, were measured by anti-viral cytokine production, pre- and 1-month post-booster dose. Monovalent and bivalent vaccines both significantly boosted Spike-specific IFN-γ production to the Wuhan-Hu-1 strain, but only the bivalent vaccine also boosted IL-2 and dual IFN-γ/IL-2 producing cells (Fig. 3A). Both vaccines induced a significant and comparable boost in IFN-γ producing T cells that were cross-reactive with Omicron BA.5, but only the bivalent vaccine also induced a significant boost in IFN-γ responses to BA.1 (Fig. 3A). Despite these observations, the fold-changes in the cytokine responses to all three variants were not significantly different between the two vaccine groups (Fig. 3B). The post-boost T cell responses of participants with or without a prior infection was not significantly different according to prior infection status (Supplementary Table S3). There was also no difference in the amount of IFN-γ or IL-2 secreted (RSV) by reactive T cells between the monovalent and bivalent vaccine groups (Supplementary Fig. S4). In summary, the monovalent and bivalent vaccines induced comparable T cell responses to the ancestral Wuhan-Hu-1 strain and the Omicron BA.5 strain, whereas the bivalent vaccine also induced Omicron BA.1 responses.Fig. 3(A) Spike-specific T cell responses were measured by IFN-y and IL-2 FluoroSpot following stimulation with Wuhan-Hu-1, BA.1 and BA.5 variant peptide pools. Circles and triangles represent pre- and post-boost timepoints, respectively. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection, respectively. Pre- and post-boost timepoints were compared by paired Wilcoxon sign ranked test. (B) Fold change in FluoroSpot cytokines between pre- and post-booster, across Wuhan-Hu-1, BA.1 and BA.5 peptide stimulation. Grey colour represents the monovalent vaccine group while magenta represents bivalent. Box plots display the median and interquartile range, and whiskers display min to max. Significance was measured using Mann–Whitney tests. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. (A) Spike-specific T cell responses were measured by IFN-y and IL-2 FluoroSpot following stimulation with Wuhan-Hu-1, BA.1 and BA.5 variant peptide pools. Circles and triangles represent pre- and post-boost timepoints, respectively. Blue and red points represent the participants that have no or prior SARS-CoV-2 infection, respectively. Pre- and post-boost timepoints were compared by paired Wilcoxon sign ranked test. (B) Fold change in FluoroSpot cytokines between pre- and post-booster, across Wuhan-Hu-1, BA.1 and BA.5 peptide stimulation. Grey colour represents the monovalent vaccine group while magenta represents bivalent. Box plots display the median and interquartile range, and whiskers display min to max. Significance was measured using Mann–Whitney tests. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 and ∗∗∗∗p < 0.0001. Multiple linear regression confirms bivalent vaccine effect To adjust for the effect of confounders we tested if age, sex, prior SARS-CoV-2 infection, and time to blood draw since the booster dose was statistically significantly different between the monovalent and bivalent groups. Sex, age and time to post-boost blood draw were statistically significantly different between monovalent and bivalent vaccine groups (independent t-test and chi square test, p < 0.05), while having a prior SARS-CoV-2 infection was not. The vaccine type independently determined the neutralising antibody titres at post-boost against Delta (p = 0.018), BA.1 (p = 0.006) and JN.1 variants (p = 0.04), and the MBC count at post-boost specific for Wuhan (p = 0.015) and BA.1 variants (p = 0.04), as well as the number of MBC capable of binding multiple variants (≥2 variants RBD; p = 0.032), after adjusting for pre-boost value, age, sex and time to blood draw. Otherwise for all other comparisons performed, the post-boost value was only predicted by the corresponding pre-boost value. In summary, the bivalent vaccine induced a broader B cell and antibody-mediated immune response, when adjusted for potentially confounding factors. B and T cell responses correlate with the neutralisation titre (ID50), including to future variants Lastly, the relationships between the B cell response, T cell response and neutralisation titre were examined (Fig. 4). There were significant, moderate correlations (p < 0.05, r = 0.40–0.59) between the neutralisation titre for Wuhan-Hu-1, Delta, BA.1 and BA.5 variants, and cross-binding MBCs (Delta + BA.5+, Wuhan-Hu-1+Delta + BA.1+, and Wuhan-Hu-1+Delta + BA.1+BA.5+), as well as BA.1-specific MBC. There was also a weak but significant correlation of these cross-binding MBCs with JN.1 nAbs. Some T cell responses, specifically, IFN-γ responses to Wuhan-Hu-1 and BA.5 Spike, also showed a significant moderate correlation with nAb titres across multiple variants.Fig. 4Correlation heatmap of neutralisation antibodies, RBD-specific memory-B cells, Spike-specific T cells and age for the study cohort. The colour scale represents the strength of the correlation coefficients, with blue indicating negative correlations and red indicating positive correlations. The size of the dot corresponds to the r-value; larger dots represent strong correlations while smaller dots represent weaker correlations. Only significant (p < 0.05) correlations are displayed. The black box highlights the correlation between cross-reactive MBCs and neutralising antibody titres. W; Wuhan-Hu-1. D; Delta. B1; BA.1. B5; BA.5. Dual; IFN-y/IL-2 double positive. Correlation heatmap of neutralisation antibodies, RBD-specific memory-B cells, Spike-specific T cells and age for the study cohort. The colour scale represents the strength of the correlation coefficients, with blue indicating negative correlations and red indicating positive correlations. The size of the dot corresponds to the r-value; larger dots represent strong correlations while smaller dots represent weaker correlations. Only significant (p < 0.05) correlations are displayed. The black box highlights the correlation between cross-reactive MBCs and neutralising antibody titres. W; Wuhan-Hu-1. D; Delta. B1; BA.1. B5; BA.5. Dual; IFN-y/IL-2 double positive. Discussion Several studies examining neutralising antibodies post-bivalent COVID-19 booster vaccination in comparison to monovalent boosters have reported increased neutralisation potency and breadth,4,6,7,34,35 but there is a lack of studies comparing how this breadth relates to MBC and T cell responses. To address this, antigen-specific MBCs were analysed using spectral flow cytometry, SARS-CoV-2 peptide-stimulated T cell IFN-γ and IL-2 expression by FluoroSpot and live virus neutralisation to compare immune responses between the vaccine types. In line with concurrent reports,6,7,36 the bivalent BA.1 vaccine induced a superior nAb response compared to the monovalent vaccine. Notably, in our study the bivalent BA.1 vaccine also produced a significantly higher neutralisation titre against the latest JN.1 variant.T This is particularly significant because this variant had not yet emerged when these participants were sampled. We also show the fold-change in neutralisation titre between the pre- and post-boost was higher in bivalent booster group compared to the monovalent against the BA.1 and JN.1 variants. These findings are noteworthy as they show that the bivalent vaccines not only provided superior protection against the variant included in the vaccine, but also induced superior protection against a future variant. This suggests that boosting with divergent Spike glycoproteins could increase the breadth of immune responses against future dominant variants as an alternative vaccine approach to targeting the most recent variant in circulation. Our study showed an increase in antigen-specific MBCs 1-month post-boost against all variants in both vaccine groups. This is likely due to the rapid recall and proliferation of MBCs targeting conserved epitopes that were formed during the previous vaccination or infection. Several studies in humans have shown that monovalent boosters do result in MBCs being recalled to the germinal-centre and to mature and broaden their specificity to bind other variants.15,16,37,38 However, these studies have only looked at the frequency of the responses to the variants as a whole polyclonal population and do not report the cross-reactivity of the individual MBC. Therefore, it was not clear whether this broadening of the polyclonal response was due to the development of multiple MBCs with unique specificities or expansion of broadly cross-reactive MBCs. This distinction is important as the latter would suggest that these ‘broader’ binding B cells may be more likely to have the capacity to respond to future variants. In our study, which also supported the finding that at the polyclonal level there was a general increase in cross-reactive responses, we demonstrated that the bivalent vaccine was more effective in promoting expansion of cross-reactive MBCs at the individual cell level compared to the monovalent vaccine. We found two studies that have tried to similarly examine B cell breadth at the single cell level in different settings, the first15 reported that the Wuhan-specific B cells had good breadth after the 3rd dose of a monovalent mRNA vaccine and could simultaneously bind the Alpha, Beta, Delta and Omicron variants. In addition to this finding, we have shown that both the monovalent and bivalent mRNA boost increase the breadth and potency of the MBCs, but the bivalent mRNA boost is superior to monovalent in generating a broader MBC response against the multiple variants. The second study20 examined how breakthrough infection with BA.1 variant lead to a robust recall response that expanded MBCs against epitopes shared broadly among variants, rather than inducing only BA.1-specific B cells. These findings together with our study, show that exposure to the BA.1 antigen, both by vaccination and natural infection, broadens the MBC cross-reactivity against novel variants and we also showed that cross-reactive MBCs also correlated with higher neutralisation titres to multiple variants. This suggests that variant vaccines may confer an advantage to future variants if those broadly recognised sites remain conserved and are target neutralising epitopes. This could be confirmed in future with single cell sorting and B cell receptor sequencing. SARS-CoV-2 vaccine-induced T cell responses tend to be more persistent than nAbs. BA.1 and BA.4/BA.5 bivalent booster vaccines have consistently been shown, including in this study, not to further enhance the magnitude of T cell effector cytokines more than slightly.7,12,13,39,40 In the current study, while the bivalent booster vaccine was superior to the monovalent vaccine in slightly increasing BA.1-directed T cell responses, the two vaccines were equivalent in terms of the fold-change increase for each variant and could not be described as increasing the breadth of the T cell response. Others have similarly concluded that despite evasion of nAbs by Omicron subvariants, a high degree of T cell cross reactivity is induced by the original monovalent mRNA vaccines and this is not augmented by vaccine boosters.12,13,39 The reason for this is that most T cell target Spike epitopes that are outside the mutatedregions with the result that 90% of Spike-specific T cells are cross-reactive.41,42 Given their persistence and resistance to viral evasion and the ongoing protectiveness of hybrid immunity in the face of waning nAb levels,43 T cells are likely to be contributing significantly to protection. Cross-reactive T cells also showed some correlation with cross-reactive nAbs as shown by this study and that of Urshchel et al.12 Limitations to the study include the small sample size and an imbalance in some cohort characteristics. However, when these differences were accounted for, the key findings of increased neutralisation and MBC breadth in the bivalent vaccine group remained significant. Another possible confounder is that the bivalent vaccine group was recruited ∼4 months after the monovalent group, potentially increasing the chance of exposure to the BA.5 variant, although the reported rate of SARS-CoV-2 infection in NSW was low over this period. Another limitation was that JN.1 had not emerged when the B cell experiments were performed and hence could not be included in the tetramer panel. In addition, the T cell analysis was conducted using peptide pools that only covered the mutated regions in BA.1 and BA.5 and these results could therefore not be compared in magnitude directly to the Wuhan-Hu-1 peptide pool, although comparisons between monovalent and bivalent vaccine groups were still valid for these peptide pools. These findings can be well generalised to the larger VIIM cohort which was randomly obtained from the Sydney, NSW population, especially since age was not found to influence the effect of vaccine type, although this may not be generalisable to other populations with higher rates of break through infection and/or lower booster vaccine uptake. In summary, this study suggests that the reason for the increased neutralising antibody breadth observed in the serum from participants receiving the bivalent vaccine is due to the enrichment of broadly binding B cells. Therefore, the increase in broadly reactive B cells may confer an advantage against novel emerging variants. Contributors Conceptualisation, S.G.Tu., K.J.S., R.A.B., A.L.C., Formal Analysis, L.B.S., K.T., A.S., N.L.F., C.R., R.R., K.J.S., R.A.B., Accessed and verified underlying data, L.B.S., K.T., A. Ag., N.L.F., C.F., A.Ak., S.G.Tu., K.J.S., R.A.B., Investigation, L.B.S., K.T., A.Ag., A.S., N.L.F., C.F., A.Ak., Data Curation, S.L., Writing – Original Draft, L.B.S., K.T., N.T., S.G.Tu., K.J.S., R.A.B., A.L.C., Writing – Review & Editing, L.B.S., K.T., A.Ag., N.L.F., A.Ak., C.R., N.T., S.L., A.R.L., F.B., W.J.B., A.K., I.D.C., M.W.D., R.R., S.G.Ta., S.G.Tu., K.J.S., R.A.B., A.L.C., Visualisation, L.B.S., K.T., N.L.F., R.R., S.G.Tu., K.J.S., R.A.B., A.L.C., Supervision, N.T., S.G.Tu., K.J.S., R.A.B., A.L.C., Funding Acquisition, S.L., A.R.L., F.B., W.J.B., A.K., I.D.C., M.W.D., S.G.Ta., J.A.T., S.G.Tu., K.J.S., R.A.B., A.L.C., All co-authors reviewed and approved the final manuscript. The VIIM consortium contributed to funding acquisition, recruitment and blood draws, sample processing and conceptualisation of this study. Data sharing statement Relevant study data is available upon request from the corresponding author, and with approval of all appropriate institutional review boards. Declaration of interests The VIIM Collaborative Group of NSW was funded by NSW Health. A.L.C has received NSW Health grant and performed consultancies for Moderna with honoraria directed to his institution. K.J.S. has received honoraria for talks from Moderna. A.K. has grants from NSW Health, NHMRC, MRFF, NIH, Viiv, Unitaid, DFAT, received consulting fee from Merck and Viiv, travel support from HIN STRIVE investigators meeting, performed leadership and advisory role in Board member Scientia Clinical Research Phase 1 Unit, HIV-NAT Advisory Board ASCOT Trial, Chair of DSMB Aegros Advisory Board and pending patent for siRNA for COVID-19. F.B. has received support from NHMRC, Novartis and MRFF. W.J.B. has received support from NSW Vaccine Accelerator, NHMRC, MRFF and NSW Dust Diseases board. I.D.C. has clinical trials support from Eli Lilly and Boehringer. M.W.D has grants from NHMRC and Gilead Australia, payment from Roche Diagnostics for webinar, GSK travel grant and participated as advisor in Gilead and GSK. R.A.B. and R.R. have NHMRC Investigator grants. S.G.Ta has grants from NHMRC, Job Research Foundation and Allegry and Immunology Foundation of Australasia. S.G.Tu has received grants from MRFF, and New South Wales Health COVID-19 Research Grants Round 2.